Systemic Nalbuphine Versus Intravenous Regional Anesthesia
NCT ID: NCT03150732
Last Updated: 2024-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
82 participants
INTERVENTIONAL
2022-08-10
2024-02-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparsion Between Intrathecal Fentanyl and Intravenous Nalbuphine As a Postoperative Analgesia in Lower Limb Surgeries
NCT06720506
A Comparative Study Between Analgesic Effect of Opioid Free and Opioid Based Anesthesia in Radical Nephrectomy Surgery
NCT05312541
Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia
NCT00738192
Evaluation of Postoperative Pain in Cases Undergoing Cataract Surgery Under Topical Versus General Anesthesia
NCT07287683
Rectus Sheath Block: Postoperative Analgesia and Proinflammatory Cytokines
NCT03074097
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Systemic nalbuphine group
53 patients will receive nalbuphine systemically
Systemic nalbuphine
Patients will receive systemic nalbuphine 10 mg
Local nalbuphine group
53 patients will receive nalbuphine with local intravenous regional anesthesia (IVRA)
Local nalbuphine
Patients will receive local nalbuphine 10 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Systemic nalbuphine
Patients will receive systemic nalbuphine 10 mg
Local nalbuphine
Patients will receive local nalbuphine 10 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Allergy to study medications
* Body mass index \> 35 kg/ m2
* Patients with sickle cell or Reynaud diseases
* Patients with a history of psychiatric illness or on chronic opioids
20 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mohamed Bakri
Professor of anesthesia & ICU
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mohamed H Bakri
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000087273
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.